| Purpose | AGM Date | Announcement Date |
|---|---|---|
| AGM | 25 Sep 2026 | 3 Sep 2026 |
| AGM 25/09/2026 We are submitting herewith the notice convening the 9th Annual general Meeting of the Company and Annual Report for the financial year 2025-26 We are submitting herewith the Corrigendum to the Annual Report of the Company for the financial year 2025-26. (As per BSE Announcement dated on: 09.09.2026) Proceedings of the 9th Annual General Meeting of the Company held on September 25, 2026 (As Per BSE Announcement Dated on 25.09.2026) Senores Pharmaceuticals Limited has informed the Exchange regarding Scrutinizer Report and Voting results of 09th Annual General Meeting (As per BSE Announcement dated on: 28.09.2026) | ||
The acquisition will be carried out in two tranches and has received approval from the management committee of the company’s board.
Senores Pharmaceuticals intends to fund the acquisition through proceeds from its IPO, which raised ₹5.82 billion in December.
Senores Pharmaceuticals shares closed 6% below their listing price, although they are still up 43% from the IPO price.
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2026, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132 (Member ID - NSE: 10975 BSE: 179 MCX: 55995 NCDEX: 01249), DP SEBI Reg. No. IN-DP-185-2016, IA SEBI Regn. No: INA000000623, Merchant Banker SEBI Regn. No. INM000010940, RA SEBI Regn. No: INH000000248, BSE Enlistment Number (RA): 5016, AMFI-Registered Mutual Fund Distributor & SIF Distributor
ARN NO : 47791 (Date of initial registration – 17/02/2007; Current validity of ARN – 08/02/2027), PFRDA Reg. No. PoP 20092018, IRDAI Corporate Agent (Composite) : CA1099
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
